{
  "docId": "019de071-41d7-735b-bdce-76898f0847d2",
  "docSlug": "eaafde7daeccaea38d88b7264ade91c5",
  "documentTitle": "Erasca | IPO Presentation Deck | 46 slides",
  "authorId": "erasca",
  "authorName": "Erasca",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 46,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "balanced",
  "nDataPoints": 45,
  "notes": "The slide uses a checkmark for owned/licensed programs and a 'P' for partnered programs, highlighting Erasca's broad coverage compared to peers.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-41d7-735b-bdce-76898f0847d2/12",
  "deckHref": "/decks/019de071-41d7-735b-bdce-76898f0847d2",
  "deckJsonHref": "/decks/019de071-41d7-735b-bdce-76898f0847d2.json",
  "deckAnchorHref": "/decks/019de071-41d7-735b-bdce-76898f0847d2#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.4,
        "x": 0.15,
        "y": 0.9
      },
      "kind": "disclaimer",
      "text": "1 Erasca's KRAS G12Ci is the only one we believe to be CNS-penetrant; 2 RASi is in TheRas and SHP2i is in Navire; 3 Novartis may not be actively developing its EGFR program",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e6a9023b-5dd3-4aa4-9a62-d05aacd767e7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.35,
        "x": 0.16,
        "y": 0.086
      },
      "kind": "legend",
      "text": "Program is fully owned or licensed; Program is partnered",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "de511d39-4f95-405c-8e7f-74ad8714444d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.94,
        "x": 0.03,
        "y": 0.14
      },
      "kind": "table",
      "text": "Competitive matrix of companies vs targets (EGFR, SHP2, SOS1, KRAS G12C, KRAS G12D, RAS-GTP, ERK1/2, ULK, MYC)",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b1ccc555-8aff-41c1-a4ef-b82076517bc6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "Companies with common cause of targeting RAS/MAPK to defeat cancer",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0366f2ca-cdc6-44a4-bb67-98e297cc40ac",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "fd871d71-6775-4812-ba28-58cdde437588",
      "evidence": "Competitive matrix of companies vs targets",
      "confidence": 0.5
    }
  ],
  "frameworks": [
    {
      "name": "competitive-landscape-matrix",
      "slug": null,
      "matchId": "73489012-9bc0-4eeb-8987-72485c254acb",
      "evidence": "Grid-based comparison of company assets against industry targets",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}